Navigation Links
Experimental Staph Vaccine Fails to Work, Study Finds
Date:4/2/2013

TUESDAY, April 2 (HealthDay News) -- An experimental vaccine does not reduce the risk of staph infections in patients who have had heart or chest surgery, a large new study finds.

The study included more than 7,000 thousand adult cardiothoracic patients. About half of them received an injection of the "V710" vaccine 14 to 60 days before their surgery, while the others received a placebo.

At 90 days after surgery, Staphylococcus aureus infections showed up in 22 of 3,528 vaccinated patients and in 27 of 3,517 patients who received the placebo. No significant differences in effectiveness were ever seen between the vaccine and placebo groups during the study.

The researchers also found that patients who received the vaccine had more negative side effects in the 14 days after vaccination than those who received the placebo (31 percent vs. 22 percent), including serious problems (1.7 percent vs. 1.3 percent).

In addition, patients who received the vaccine were much more likely to suffer multi-organ failure at some point in the study (31 vs. 17 events), according to the study in the April 3 issue of the Journal of the American Medical Association.

The difference in the death rate from all causes was not statistically significant between the groups of patients (201 of 3,958 vs. 177 of 3,967), but the death rate among patients who developed staph infections was much higher among those who received the vaccine (15 of 73 vs. 4 of 96), according to a journal news release.

"These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," concluded Dr. Vance Fowler Jr., of Duke University Medical Center, and colleagues.

Dr. Preeti Malani, of the University of Michigan Health System, wrote an accompanying journal editorial.

"While the prevention of S. aureus infections should remain a priority for future investigation, novel approaches must move beyond vaccine strategies -- and for that matter, beyond S. aureus. Even if a viable staphylococcal vaccine were to be developed, this would not address non-S. aureus infections," Malani wrote.

More information

The U.S. Centers for Disease Control and Prevention discusses surgical site infections.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, April 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Work Against Hepatitis C
2. Experimental Alzheimers Drug Shows Promise, Study Finds
3. Experimental Vitiligo Treatment Shows Promise in Mice
4. Harmful effects of bisphenol A proved experimentally
5. Experimental agent briefly eases depression rapidly in test
6. NIH-funded trial launched to assess experimental TB drug
7. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
8. Experimental Antidepressant Appears Quick-Acting, Safe
9. More than a third of high-risk leukemia patients respond to an experimental new drug
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Experimental Insomnia Drug Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Staph Vaccine Fails to Work, Study Finds
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... a historic vote among its members this weekend, the Shinnecock Indian Nation ... and dispensary on tribal land near Southampton . ... for patients in the state,s Medical Cannabis Program. --> ... in the state,s Medical Cannabis Program. --> Tribal members ... designation from the State of New York as ...
(Date:2/8/2016)... Feb. 8, 2016  A research team led by ... discovered details of how the abnormal breakage and rearrangement ... aggressive form of acute lymphoblastic leukemia (ALL). Such leukemias ... mutations trigger overproduction of immature cells, called lymphoblasts. ... of the malfunction underlying the type called "Ph-like ALL" ...
(Date:2/8/2016)... Feb. 8, 2016 http://www.researchandmarkets.com/research/x6mkjm/knee ... "Knee Reconstruction Devices Market by Product Type (Primary ... Geography (U.S., Canada, Eu-5, Japan, Bric, Turkey, Indonesia ... report to their offering. --> ... "Knee Reconstruction Devices Market by Product Type ...
Breaking Medicine Technology: